5 min read

Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate

By Catherine Hanley on Jul 6, 2020 9:35:00 AM

  • Emergent will provide contract development and manufacturing services beginning in 2021 to produce drug substance at large scale for commercial manufacturing with first two years valued at approximately $480 million
  • For the remaining three years beginning in 2023, Emergent will provide a flexible capacity deployment model to support annual dose requirements

GAITHERSBURG, Md., July 06, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing for Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac® technology. Emergent will provide contract development and manufacturing (CDMO) services to produce drug substance at large scale over five years, valued at approximately $480 million for the first two years.

Topics: COVID-19 news
5 min read

Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate

By Catherine Hanley on Jun 11, 2020 3:45:36 PM

  • Emergent will provide contract development and manufacturing services and secure large-scale manufacturing capacity through 2020 to support AstraZeneca’s COVID-19 vaccine candidate
  • Agreement valued at approximately $87 million

GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it will deploy its molecule-to-market contract development and manufacturing (CDMO) services to support the manufacturing of AstraZeneca’s vaccine candidate for COVID-19, AZD1222, a viral vector-based, weakened version of adenovirus containing the genetic material of SARS-CoV-2 spike protein, developed by Oxford University’s Jenner institute working with the Oxford Vaccine Group.

Topics: COVID-19
1 min read

Emergent Continues to Expand Role in Support of Development and Manufacturing of COVID-19 Vaccines

By Catherine Hanley on Jun 2, 2020 9:30:00 AM

Emergent BioSolutions recently announced that it has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS), to deploy its contract development and manufacturing (CDMO) capacities, capabilities, and expertise to support the U.S. government’s efforts to accelerate delivery of COVID-19 vaccines.

Topics: COVID-19
6 min read

Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing

By Catherine Hanley on Jun 1, 2020 6:45:00 AM

  • Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid domestic production of leading COVID-19 vaccine candidates through 2021  
  • Emergent will provide molecule-to-market CDMO services and commit manufacturing capacity, valued at approximately $542.7 million, paving the way for pharmaceutical and biotechnology innovators to advance COVID-19 programs
  • Task order also includes approximately $85.5 million for expansion of Emergent’s viral and non-viral CDMO drug product fill/finish capacity

GAITHERSBURG, Md., June 01, 2020 (GLOBE NEWSWIRE)  - Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS), to deploy its contract development and manufacturing (CDMO) capacities, capabilities, and expertise to support the U.S. government’s efforts to accelerate delivery of COVID-19 vaccines.

Topics: COVID-19
1 min read

May 4th Webinar: Rapid Readiness for Pandemic Response

By Catherine Hanley on Apr 26, 2020 5:09:37 PM

Watch our latest webinar on the topic of how drug developers can maximize capacity, capabilities and expertise for pandemic response. This presentation is Part 2 in a Coronavirus Virtual Series brought to you by FiercePharma with featured speaker Sean Kirk, EVP Manufacturing & Technical Operations.

Topics: COVID-19 webinar
4 min read

Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19

By Catherine Hanley on Apr 26, 2020 5:03:01 PM

GAITHERSBURG, Md., April 23, 2020 (GLOBE NEWSWIRE)

Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement whereby Emergent will deploy its contract development and manufacturing (CDMO) services to support the manufacturing of Johnson & Johnson’s lead vaccine candidate for COVID-19 that leverages the AdVac® and PER.C6® technologies from the Janssen Pharmaceutical Companies of Johnson & Johnson.

Topics: COVID-19 J&J
1 min read

Webinar: Finding Solutions for public health threats: COVID-19

By Catherine Hanley on Apr 17, 2020 12:04:47 PM

What are innovators doing to speed up the path to treating and preventing COVID-19?

The novel coronavirus has quickly taken over many aspects of the daily lives of people around the globe, stressing the healthcare system and putting

scientists at the forefront of this pandemic. Explore this new topic with Dr. Richard Welch, as he discusses how companies are mounting a rapid and effective response to the current challenges of the latest public health threats.

Topics: COVID-19
1 min read

Novavax + Emergent: In the news

By Catherine Hanley on Mar 23, 2020 8:08:22 AM

Original news coverage of Novavax's agreement with Emergent BioSolutions to manufacture and develop an experimental oral vaccine candidate for the Coronavirus Disease.

Topics: Novovax COVID-19
1 min read

Vaxart + Emergent: In the news

By Catherine Hanley on Mar 23, 2020 8:05:18 AM

Original news coverage of Vaxart's agreement with Emergent BioSolutions to manufacture and develop an experimental oral vaccine candidate for the Coronavirus Disease.

Topics: COVID-19 Vaxart
3 min read

Vaxart AGREEMENT for Experimental Oral Vaccine Candidate for Coronavirus Disease

By Catherine Hanley on Mar 18, 2020 10:14:34 PM

GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its molecule-to-market contract development and manufacturing (CDMO) services to develop and manufacture Vaxart’s experimental oral vaccine candidate for coronavirus disease (COVID-19). Development services will begin immediately, and upon Vaxart’s election, Emergent agrees to produce clinical material expected to enable Vaxart to initiate a Phase 1 clinical study anticipated early in the second half of 2020. Vaxart’s oral recombinant vaccine candidate is based on its proprietary VAAST™ platform.

Topics: COVID-19 Vaxart

Featured